Cost Is the Biggest Barrier to Apremilast Adherence — Here's How to Address It

You prescribe Apremilast (Otezla) because it works. It's an effective oral option for plaque psoriasis, psoriatic arthritis, and Behcet's disease oral ulcers — no injections, no infusion centers, no routine lab monitoring. For the right patient, it's an excellent choice.

But here's the problem your patients aren't always telling you about: they can't afford it.

At $5,000 to $6,800 per month without insurance, Apremilast is one of the more expensive oral medications in dermatology and rheumatology. Even with insurance, prior authorization hurdles, specialty pharmacy requirements, and significant copays create friction that leads to abandoned prescriptions and poor adherence.

This guide provides a practical framework for helping your patients access Apremilast affordably — including manufacturer programs, discount options, alternative strategies, and how to build cost conversations into your clinical workflow.

What Your Patients Are Actually Paying

Understanding the real-world cost landscape helps frame the conversation:

Without Insurance

• Cash price: $5,000-$6,800 for a 30-day supply (60 tablets of 30 mg)
• No generic available: While the FDA has approved generic Apremilast ANDAs, patent litigation has blocked commercial launch until approximately 2028-2029
• Specialty pharmacy dispensing: Most plans require specialty pharmacy, limiting price shopping

With Commercial Insurance

• Prior authorization: Required by virtually all payers — expect 3-14 days processing
• Step therapy: Many plans require documented failure on Methotrexate or another systemic before approving Apremilast
• Copays: Tier 4-5 specialty drug copays typically range from $100-$500+/month without manufacturer assistance
• Specialty pharmacy mandate: Limits patient choice and may create shipping delays

Medicare Part D

• Apremilast is covered but typically placed on specialty tiers
• Medicare patients cannot use manufacturer copay cards (Anti-Kickback Statute)
• Out-of-pocket costs can be substantial, especially in the coverage gap
• Patient assistance programs (not copay cards) may help qualifying Medicare patients

Manufacturer Savings Programs: Amgen SupportPlus

Amgen runs one of the more comprehensive patient support programs in specialty pharma. Knowing these programs well — and proactively connecting patients — can dramatically improve access.

Co-Pay Savings Program

• Eligibility: Commercially insured patients (not Medicare, Medicaid, or government-funded programs)
• Benefit: Eligible patients may pay as little as $0 copay
• How to enroll: Patients can enroll at Otezla.com or by calling 1-833-44AMGEN (1-833-442-6436)
• Your role: Mention this at the point of prescribing. Hand the patient a brochure or have your staff help them enroll before they leave the office.

Bridge to Commercial Coverage

This is one of the most underutilized programs:

• What it does: Provides free Otezla for up to 12 prescription fills while prior authorization is being processed
• Why it matters: Eliminates the gap between prescribing and insurance approval — the window where many patients give up
• How to activate: Your office submits the request through Amgen SupportPlus concurrently with the PA submission

This program alone can prevent a significant number of prescription abandonments. If your practice isn't routinely activating it, you're leaving adherence on the table.

Amgen Safety Net Foundation

• Eligibility: Uninsured or underinsured patients who meet income requirements
• Benefit: Otezla at no cost
• Application: Through Amgen SupportPlus or by calling 1-833-44AMGEN
• Your role: For uninsured patients, initiate this conversation before writing the prescription. A patient who knows there's a path to free medication is far more likely to follow through.

Coupon and Discount Card Options

Because no generic Apremilast is currently available, traditional discount card programs (GoodRx, SingleCare, etc.) offer limited value — the cash price remains $5,000+/month regardless. However, they can still be useful in specific situations:

• GoodRx: Shows pharmacy pricing comparisons and may offer modest savings off the cash price at certain pharmacies
• SingleCare and RxSaver: Similar pricing tools — worth checking but don't expect dramatic discounts on a brand-only specialty drug
• Amgen Co-Pay Program: For commercially insured patients, this is far more impactful than any third-party discount card

Provider tip: Don't waste time with discount cards for Apremilast. Direct patients to the manufacturer programs first — they're significantly more effective for this particular medication.

Generic Alternatives and Therapeutic Substitution

Since generic Apremilast isn't available yet, "generic alternative" really means therapeutic substitution — prescribing a different medication in the same or similar class. Here are the options worth discussing with cost-sensitive patients:

Methotrexate

• Cost: $10-$50/month (generic)
• Trade-offs: Requires regular blood work (liver function, CBC), cannot be used in pregnancy, has more systemic side effects
• When to consider: For patients where cost is the primary barrier and they haven't tried Methotrexate, this may be a reasonable first step — and it often satisfies step therapy requirements for future Apremilast approval

Deucravacitinib (Sotyktu)

• Cost: Similar brand pricing, but different manufacturer programs may offer better coverage for some patients
• Trade-offs: Different mechanism (TYK2 inhibitor), potentially better efficacy, different side effect profile
• When to consider: If insurance denies Apremilast but covers Deucravacitinib, or vice versa

Biosimilar Adalimumab

• Cost: Multiple Adalimumab biosimilars are now available at lower cost than the original Humira
• Trade-offs: Injectable, more significant immunosuppression, requires monitoring
• When to consider: For patients with moderate-to-severe disease who may benefit from greater efficacy and whose insurance offers favorable coverage for biosimilars

Building Cost Conversations Into Your Clinical Workflow

The most impactful thing you can do isn't prescribing a specific savings program — it's making cost a routine part of the clinical conversation. Here's how:

At the Point of Prescribing

1. Ask about cost concerns: "Before I send this prescription, let's talk about cost. Do you know what your plan covers for specialty medications?"
2. Present the savings options proactively: Don't wait for patients to tell you they can't afford it — many will just silently abandon the prescription
3. Activate the Bridge program: Submit the PA and the Bridge to Commercial Coverage request simultaneously so the patient can start treatment immediately

Empower Your Staff

• Train your medical assistants or patient coordinators to initiate Amgen SupportPlus enrollment at the time of prescribing
• Keep Otezla co-pay program brochures in exam rooms and checkout areas
• Assign a staff member to follow up on PA status within 48 hours

Follow Up on Prescription Fill Status

• Check back at 2 weeks: Has the patient actually received the medication?
• If not: What's the barrier? PA denial? Cost? Pharmacy confusion?
• For PA denials: Initiate a peer-to-peer review promptly — many denials are overturned

Use Technology to Streamline Access

Direct your patients and staff to tools that simplify the process:

• Medfinder for Providers — helps your patients find pharmacies with Apremilast in stock and connects them with savings programs
• Electronic prior authorization (ePA) — if your EHR supports it, use electronic PA submission to reduce turnaround time
• Specialty pharmacy relationship: Build a direct contact at the specialty pharmacies your patients use most frequently

Quick Reference: Decision Tree for Patient Cost Assistance

1. Commercially insured? → Enroll in Amgen Co-Pay Program ($0 copay) + activate Bridge to Commercial Coverage
2. Medicare Part D? → Apply to Amgen Safety Net Foundation (co-pay cards not eligible) + check for Extra Help/LIS eligibility
3. Uninsured? → Apply to Amgen Safety Net Foundation (free medication)
4. Underinsured / high copay? → Amgen Safety Net Foundation + explore therapeutic substitution if needed
5. PA denied? → Peer-to-peer review + appeal + Bridge program in the meantime

Final Thoughts

Apremilast is a valuable treatment option that too many patients never start or stop taking because of cost. As prescribers, we have more leverage over this problem than we often realize — not through clinical decisions alone, but by systematically connecting patients with the financial support programs that already exist.

The manufacturer programs for Otezla are robust. The Bridge to Commercial Coverage program is genuinely useful. The Safety Net Foundation fills gaps for uninsured patients. But none of these programs work if patients don't know about them.

Make cost a clinical conversation. Train your staff to activate savings programs at the point of prescribing. Follow up on fill status. These small workflow changes can have an outsized impact on treatment adherence and patient outcomes.

For more resources, visit Medfinder for Providers — we help providers and patients navigate medication access, availability, and affordability.